Pulse Biosciences’ nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting
Clinical Data on Benign Thyroid Nodule Ablation to be highlighted in presentation
“We believe the differentiated nPulse Vybrance Percutaneous Electrode system is setting a new standard for safety, efficacy, and workflow efficiency,” said Paul LaViolette, Co-Chairman and CEO of Pulse Biosciences. “We have recently treated our first patients in our multicenter IRB study, and going into the second half of 2025, we are excited to expand the body of clinical evidence supporting the treatment of benign thyroid nodules with our nPulse technology. We look forward to our novel nanosecond PFA energy being highlighted at the prestigious ATA meeting and we are thankful for continued support of the clinicians investigating our technology.”
The Company will highlight its nPulse Technology at several events at the ATA 2025 Annual Meeting including:
Friday, September 12th, 2025 |
Presentation | Late Breaking Oral Abstract – Session #2 |
Time: 4:10 pm to 5:10 pm PT |
Location: Exhibit Hall – Poster Area |
Ralph Tufano, M.D. – Sarasota Memorial Hospital, |
|
Saturday, September 13th, 2025 |
Pulse Biosciences Sponsored Event |
Clinical Experience with Next Generation Nonthermal Ablation Technology |
Time: 10:25 am to 11:25 am PT |
Location: Expo Theater |
Ralph Tufano, M.D. – Sarasota Memorial Hospital, |
Prof. Stefano Spiezia – Ospedale del Mare, |
Emad Kandil, M.D., Tulane Medicine, |
Vania Nose, M.D., Ph.D., UT Southwestern, |
|
nPulse Vybrance Exhibit | Exhibit Hall |
Sept 11: 10:15 a.m. - 6:30 p.m. |
Sept 12: 10:15 a.m. - 4:30 p.m. |
Sept 13: 10:15 a.m. - 1:00 p.m. |
Location: Booth #315- Kierland Grand Ballroom (2nd level) |
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation.
Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA, nanosecond PFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company’s nPulse technology and nPulse System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning the Company’s future commercialization and product development efforts and whether those efforts will be successful, statements concerning early clinical successes and whether they are predictive of the safety and effectiveness of any medical device, such as the nsPFA 360° Cardiac Catheter System, the nsPFA Cardiac Surgical System, and the nsPFA Percutaneous Electrode System, and statements concerning the Company’s future clinical and regulatory initiatives anywhere in the world, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250910065399/en/
Investors:
Pulse Biosciences, Inc.
Jon Skinner, CFO
IR@pulsebiosciences.com
Or
Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com
Source: Pulse Biosciences, Inc.
